‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Neurochemistry

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1471-4159.2011.07458.xPMID 21883222
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for Alzheimer's disease.

  2013influential reference
• Managing Cognitive Dysfunction through the Continuum of Alzheimer’s Disease

  2011cited by this paper
• Amyloid‐related imaging abnormalities in amyloid‐modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup

  2011cited by this paper
• Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

  2011cited by this paper
• Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease

  2010cited by this paper
• Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

  2010influential reference
• Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

  2010cited by this paper
• 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

  2010cited by this paper
• Biomarkers in Alzheimer's Disease

  2009cited by this paper
• Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

  2009cited by this paper
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

  2009cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice

  2008cited by this paper
• Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

  2008cited by this paper
• Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

  2008cited by this paper
• Immunotherapy for Alzheimer's disease

  2006cited by this paper
• Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

  2005cited by this paper
• Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

  2005cited by this paper
• Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β

  2005cited by this paper
• Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

  2005cited by this paper
• Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

  2005influential reference
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005influential reference
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

  2001cited by this paper
• Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper

• The Importance of Vaccines in Preventing Impending Alzheimer's Epidemic.

  2025cites this paper
• QS-21: Structural insights, immunological mechanisms, and prospects for rational design of safer vaccine adjuvants.

  2025cites this paper
• Targeting protein misfolding in Alzheimer's disease: The emerging role of molecular chaperones.

  2025cites this paper
• A Comprehensive Review on Alzheimer’s Disease; Pathophysiology and Treatment

  2024cites this paper
• Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer’s Disease

  2023cites this paper
• Understanding Alzheimer's Disease and its Metal Chelation Therapeutics: A Narrative Review.

  2023cites this paper
• Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer's Disease.

  2023cites this paper
• Beneficial Effect of ACI-24 Vaccination on Aβ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model

  2022cites this paper
• Natural and Synthetic Saponins as Vaccine Adjuvants

  2021cites this paper
• Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease

  2021cites this paper
• Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine.

  2020cites this paper
• A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

  2020cites this paper
• Unraveling molecular signaling in neurodegenerative diseases

  2020cites this paper
• Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials

  2020cites this paper
• Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine

  2019cites this paper
• Carbon nanomaterials and amyloid‐beta interactions: potentials for the detection and treatment of Alzheimer's disease?

  2019cites this paper
• Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study

  2019cites this paper
• Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates.

  2019cites this paper
• Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death

  2019cites this paper
• Editorial: Human and Animal Models for Translational Research on Neurodegeneration: Challenges and Opportunities From South America

  2018cites this paper
• A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer’s disease

  2018cites this paper
• A monoclonal antibody targeting amyloid #_#x03B2; (A#_#x03B2;) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer#_#x2019;s disease

  2018cites this paper
• A Vaccine Kit for Prevention and Therapy of Alzheimer’s Disease in a Transgenic Mouse Model

  2018cites this paper
• Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

  2018cites this paper
• β-Amyloid Prions and the Pathobiology of Alzheimer's Disease.

  2018cites this paper
• Alzheimer's Disease: Dawn of a New Era?

  2017cites this paper
• Design optimization for clinical trials in early‐stage manifest Huntington's disease

  2017cites this paper
• Immunotherapy of Brain Cancers and Neurological Disorders

  2017cites this paper
• A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease

  2017cites this paper
• Novel Treatment Strategies Using TiO2-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease.

  2017cites this paper
• Antioxidants in the Prevention and Treatment of Alzheimer’s Disease

  2017cites this paper
• Flavonoids in Transgenic Alzheimer's Disease Mouse Models

  2017cites this paper
• Immunotherapy for the Treatment of Alzheimer’s Disease

  2017cites this paper
• New Therapeutic Targets in Alzheimer's Disease

  2017cites this paper
• A β prions and the pathobiology of Alzheimer’s disease

  2017cites this paper
• Immunomodulation via Toll-like Receptor 9: An Adjunct Therapy Strategy against Alzheimer's Disease?

  2017influential citation
• Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery

  2017cites this paper
• Method, Composition, and Kit Useful for Treatment of Alzheimer's Disease

  2017cites this paper
• Alzheimer's Disease and Immune Response: A Brief Overview

  2017cites this paper
• b -Amyloid Prions and the Pathobiology of Alzheimer’s Disease

  2017cites this paper
• Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.

  2017cites this paper
• Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide.

  2017cites this paper
• Mechanism of Anti-α-Synuclein Immunotherapy

  2016cites this paper
• Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

  2016cites this paper
• Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.

  2016cites this paper
• Extracellular α-Synuclein as a Target for Immunotherapy

  2016cites this paper
• High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide

  2016cites this paper
• Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease

  2016cites this paper
• Dementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South America

  2016cites this paper
• Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage.

  2016cites this paper
• Reduction of Blood Amyloid-β Oligomers in Alzheimer’s Disease Transgenic Mice by c-Abl Kinase Inhibition

  2016cites this paper
• ‘From past to future’ – deciphering the molecular basis of Alzheimer's disease through the pages of the Journal of Neurochemistry

  2016cites this paper
• Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules

  2016cites this paper
• Neurodegenerative Diseases and Dementia

  2016cites this paper
• Novel Therapeutic Strategies for Dementia.

  2016cites this paper
• Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments

  2016cites this paper
• Dementia and use of drugs : economic modelling and population-based studies

  2015cites this paper
• Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease.

  2015cites this paper
• Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

  2015cites this paper
• Co-immunization with DNA and protein mixture: A safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice

  2015cites this paper
• Rarity of the Alzheimer disease-protective APP A673T variant in the United States.

  2015cites this paper
• The Amyloid Precursor Protein Controls PIKfyve Function

  2015cites this paper
• Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?

  2015cites this paper
• Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

  2015cites this paper
• Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future

  2015influential citation
• Proteostasis and Chaperone Surveillance

  2015cites this paper
• A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

  2015cites this paper
• Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases

  2015cites this paper
• Aging Mechanisms

  2015cites this paper
• Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer's Disease.

  2015cites this paper
• Nanomedicine for the treatment of Alzheimer's disease.

  2015cites this paper
• Alzheimer's disease vaccine development: A new strategy focusing on immune modulation.

  2015cites this paper
• Correlations between Alzheimer’s Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment

  2015cites this paper
• Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease

  2015cites this paper
• Proteopathies: Biological, Molecular and Clinical Perspectives

  2015cites this paper
• Protein Misfolding, Neurodegeneration and Tau

  2015cites this paper
• Papel regulador de la proteína priónica celular en la enfermedad de Alzheimer y uso de gamma-péptidos como potenciales agentes terapéuticos

  2015cites this paper
• MR-spektroskopische pH-Messungen bei physiologischem Hirnaltern und Demenz

  2015cites this paper
• Nanomedicine for the Treatment of Alzheimer's Disease.

  2015cites this paper
• Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

  2014cites this paper
• Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines

  2014cites this paper
• Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease

  2014cites this paper
• Glycosphingolipids in the regulation of the nervous system.

  2014cites this paper
• A Generic Method for Design of Oligomer-Specific Antibodies

  2014cites this paper
• Epitope‐based DNA vaccine for Alzheimer's disease: Translational study in macaques

  2014cites this paper
• New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies.

  2014cites this paper
• A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.

  2014cites this paper
• Plant-based vaccines for Alzheimer's disease: an

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Amyloid β-peptide and Alzheimer's disease.

  2014cites this paper
• Strikingly Reduced Amyloid Burden and Improved Behavioral Performance in Alzheimer's Disease Mice Immunized with Recombinant Chimeric Vaccines by Hexavalent Foldable Aβ1-15 Fused to Toxin-Derived Carrier Proteins

  2014cites this paper
• Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy

  2014cites this paper
• Evaluating a new drug to combat alzheimer's disease.

  2014cites this paper
• Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients

  2014cites this paper
• Personalized Medicine of Alzheimer’s Disease

  2014cites this paper
• Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins

  2014cites this paper
• Chapter 9 – Modulation of BACE1 Activity as a Potential Therapeutic Strategy for Treating Alzheimer’s Disease

  2014cites this paper
• Alzheimer disease and cellular mechanisms of memory storage.

  2014cites this paper
• Biochemical and immunological aspects of protein aggregation in neurodegenerative diseases

  2014cites this paper
• Genetic and Environmental Influences on Intellectual Disability in Childhood

  2014cites this paper